Literature DB >> 25531792

Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions.

Jiansong Fang1, Yongjie Li, Rui Liu, Xiaocong Pang, Chao Li, Ranyao Yang, Yangyang He, Wenwen Lian, Ai-Lin Liu, Guan-Hua Du.   

Abstract

To determine chemical-protein interactions (CPI) is costly, time-consuming, and labor-intensive. In silico prediction of CPI can facilitate the target identification and drug discovery. Although many in silico target prediction tools have been developed, few of them could predict active molecules against multitarget for a single disease. In this investigation, naive Bayesian (NB) and recursive partitioning (RP) algorithms were applied to construct classifiers for predicting the active molecules against 25 key targets toward Alzheimer's disease (AD) using the multitarget-quantitative structure-activity relationships (mt-QSAR) method. Each molecule was initially represented with two kinds of fingerprint descriptors (ECFP6 and MACCS). One hundred classifiers were constructed, and their performance was evaluated and verified with internally 5-fold cross-validation and external test set validation. The range of the area under the receiver operating characteristic curve (ROC) for the test sets was from 0.741 to 1.0, with an average of 0.965. In addition, the important fragments for multitarget against AD given by NB classifiers were also analyzed. Finally, the validated models were employed to systematically predict the potential targets for six approved anti-AD drugs and 19 known active compounds related to AD. The prediction results were confirmed by reported bioactivity data and our in vitro experimental validation, resulting in several multitarget-directed ligands (MTDLs) against AD, including seven acetylcholinesterase (AChE) inhibitors ranging from 0.442 to 72.26 μM and four histamine receptor 3 (H3R) antagonists ranging from 0.308 to 58.6 μM. To be exciting, the best MTDL DL0410 was identified as an dual cholinesterase inhibitor with IC50 values of 0.442 μM (AChE) and 3.57 μM (BuChE) as well as a H3R antagonist with an IC50 of 0.308 μM. This investigation is the first report using mt-QASR approach to predict chemical-protein interaction for a single disease and discovering highly potent MTDLs. This protocol may be useful for in silico multitarget prediction of other diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25531792     DOI: 10.1021/ci500574n

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  30 in total

1.  Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.

Authors:  Wenwen Lian; Jiansong Fang; Chao Li; Xiaocong Pang; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2015-12-21       Impact factor: 2.943

2.  In silico prediction of ROCK II inhibitors by different classification approaches.

Authors:  Chuipu Cai; Qihui Wu; Yunxia Luo; Huili Ma; Jiangang Shen; Yongbin Zhang; Lei Yang; Yunbo Chen; Zehuai Wen; Qi Wang
Journal:  Mol Divers       Date:  2017-08-02       Impact factor: 2.943

3.  Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.

Authors:  Hongao Zhang; Wei Liu; Zhihong Liu; Yingchen Ju; Mengyang Xu; Yue Zhang; Xinyu Wu; Qiong Gu; Zhong Wang; Jun Xu
Journal:  Medchemcomm       Date:  2018-03-01       Impact factor: 3.597

Review 4.  Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.

Authors:  Mohammad A Khanfar; Anna Affini; Kiril Lutsenko; Katarina Nikolic; Stefania Butini; Holger Stark
Journal:  Front Neurosci       Date:  2016-05-30       Impact factor: 4.677

Review 5.  Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.

Authors:  Vertika Gautam; Anand Gaurav; Neeraj Masand; Vannajan Sanghiran Lee; Vaishali M Patil
Journal:  Mol Divers       Date:  2022-07-11       Impact factor: 3.364

6.  Rapid, quantitative therapeutic screening for Alzheimer's enzymes enabled by optimal signal transduction with transistors.

Authors:  Son T Le; Michelle A Morris; Antonio Cardone; Nicholas B Guros; Jeffery B Klauda; Brent A Sperling; Curt A Richter; Harish C Pant; Arvind Balijepalli
Journal:  Analyst       Date:  2020-03-11       Impact factor: 4.616

Review 7.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

8.  Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.

Authors:  Kushagra Kashyap; Mohammad Imran Siddiqi
Journal:  Mol Divers       Date:  2021-07-19       Impact factor: 3.364

Review 9.  Neuroprotective Potential of Ellagic Acid: A Critical Review.

Authors:  Ashutosh Gupta; Amit Kumar Singh; Ramesh Kumar; Sarah Jamieson; Abhay Kumar Pandey; Anupam Bishayee
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

10.  Identification of Multi-Target Anti-AD Chemical Constituents From Traditional Chinese Medicine Formulae by Integrating Virtual Screening and In Vitro Validation.

Authors:  Baoyue Zhang; Jun Zhao; Zhe Wang; Pengfei Guo; Ailin Liu; Guanhua Du
Journal:  Front Pharmacol       Date:  2021-07-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.